Literature DB >> 21970253

Pterygium: A review of clinical features and surgical treatment.

B I Eze1, F C Maduka-okafor, O I Okoye, C M Chuka-okosa.   

Abstract

BACKGROUND: Ptergium is a frequently encountered clinical entity in ophthalmic practice. Although commoner in the tropics compared with the temperate region, all Ophthalmologists worldwide should be conversant with the clinical features and outcome of various approaches to surgical management. A review of the efficacy of the currently available surgical procedures for pterygium excision using postoperative recurrences as the main outcome measure is presented.
METHOD: Manual and electronic (PUBMED, MEDLINE, AJOL AND HINARI) search for medical literature relevant to clinical features and surgical treatment of pterygium was conducted. Previous reviews, large case series reports, randomized controlled trials and one meta-analysis were selected and critically reviewed.
RESULTS: Postoperative recurrence is a dominant complication of pterygium excision irrespective of the adopted surgical procedure. Pterygium excision with adjunctive therapy and ocular surface reconstruction is the current procedure of choice in view of its comparatively higher efficacy in preventing recurrence.
CONCLUSION: Recurrence is the commonest postoperative complication of pterygium excision. There is need for further research into the aetiopathogenesis and risk factors for recurrence of human pterygia.

Entities:  

Mesh:

Year:  2011        PMID: 21970253

Source DB:  PubMed          Journal:  Niger J Med        ISSN: 1115-2613


  2 in total

1.  Acupoint Massage plus Recombinant Bovine Basic Fibroblast Growth Factor Ophthalmic Gel and Limbal Stem Cell Transplantation on Visual Quality, Corneal Refraction, and Aesthetic Outcome in Patients with Pterygium.

Authors:  Xiaoqin Zhang; Yu Wu
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-14       Impact factor: 2.650

2.  DNA damage in human pterygium: one-shot multiple targets.

Authors:  Anca Maria Cimpean; Mihai Poenaru Sava; Marius Raica
Journal:  Mol Vis       Date:  2013-02-07       Impact factor: 2.367

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.